Comparing the cost-effectiveness of SGLT2i versus mineralocorticoid antagonists

FHS
June 19, 2023
2:43 pm

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are approved for heart failure with reduced ejection fraction (HFrEF).

Insurance Coverages To Help Bring Psychedelic Treatments to Market | Psychedelic Invest

The revitalization of psychedelic substances for therapeutic applications has ignited significant interest in their potential as breakthrough treatments, driving a flurry of research and efforts

March 22, 2024

Is night shift work rewiring our appetite and driving weight gain?

Bristol University scientists reveal that night shift work disrupts the body’s circadian rhythm, altering appetite-regulating hormones and leading to weight gain. The study, providing insights

October 10, 2023

After Cassava Alzheimer’s drug fiasco, the FDA must intervene to protect patients

For nearly a year, my stance on Cassava Sciences and its Alzheimer’s disease drug candidate simufilam has been clear: Emerging evidence shows the drug is

October 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.